Loading
A phase 2 trial of surufatinib, toripalimab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Sun Yat-sen University, not yet recruiting.
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT07469956 by Sun Yat-sen University, with a registry enrolment figure of 30 participants, started 2026-03-31 and due to reach its primary completion in 2028-01-31. Interventions recorded: Surufatinib; Toripalimab; mFOLFIRINOX. Conditions listed: Pancreatic Cancer Resectable. Primary outcome: 12-month Event Free Survival Rate. Pancreatic eligibility wording from the registry: "Patients with high-risk resectable or borderline resectable pancreatic cancer confirmed by pathological tissue or cytology:". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/